A Phase I Study Using Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients.

Trial Profile

A Phase I Study Using Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Plerixafor (Primary) ; Cytarabine; Etoposide
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Proof of concept
  • Acronyms POETIC
  • Most Recent Events

    • 01 Aug 2017 Results published in the Pediatric Blood and Cancer
    • 10 Jun 2017 Biomarkers information updated
    • 17 Oct 2016 Planned End Date changed from 1 Jul 2014 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top